2014. ISPOR European Congress – Cost Effectiveness of Cetuximab in First-Line Treatment of RAS Wild-Type Metastatic Cancer in Scotland: A Summary of the Submission to the Scottish Medicines Consortium

Jarrett J, Ovcinnikova O, Hnoosh A, Harty G, Byrne B, von Hohnhorst P. Cost Effectiveness of Cetuximab in First-Line Treatment of RAS Wild-Type Metastatic Cancer in Scotland: A Summary of the Submission to the Scottish Medicines Consortium. Value Health. 2014 Nov;17(7):A638. Presented at: ISPOR 17th Annual European Congress; November 12, 2014; Amsterdam, The Netherlands.